Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2500380 | Farmacia Hospitalaria | 2009 | 9 Pages |
Abstract
Rivaroxaban will probably be the first available oral factor Xa (FXa) direct inhibitor anticoagulant drug. It produces a reversible and predictable inhibition of FXa activity with potential to inhibit clot-bound FXa. Its pharmacokinetic characteristics include rapid absorption, high oral availability, high plasma protein binding and a half-life of aprox. 8 hours. Rivaroxaban elimination is mainly renal, but also through faecal matter and by hepatic metabolism. Although the drug has demonstrated moderate potential to interact with strong CYP3A4 inhibitors, it does not inhibit or induce any major CYP450 enzyme.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmaceutical Science
Authors
Juan Pablo Ordovás Baines, Eduardo Climent Grana, Alejandro Jover Botella, Isabel Valero GarcÃa,